Nanexa AB announced that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 SEK | -4.55% | +23.24% | -14.63% |
May. 15 | Nanexa AB Elects Hanna Tilus as Members of the Board | CI |
May. 15 | Nanexa AB Receives Approval for NEX-22 Clinical Study | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.63% | 14.15M | |
-58.75% | 85.18M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA